[ad_1]
This article is over a month old and may contain outdated advice from authorities on coronary heart disease.
Stay up to date on the NRK overview or on the FHI website.
The phase 3 trial of the vaccine, which is being developed by AstraZeneca and the University of Oxford in various parts of the US, was discontinued after a review of the vaccine trials, writes the news website Stat .
The AstraZeneca coronary vaccine is in the final stages of testing. An AstraZeneca spokesperson described the break as “a standard routine to follow when a potentially unexplained disease is detected in a test.”
The vaccine is being tested in Phase 3 in the United States and in Phases 2 and 3 in the United Kingdom, Brazil, and South Africa.
AstraZeneca is considered one of the main candidates to develop a covid-19 vaccine, and the European Commission has signed an agreement with the pharmaceutical company. The cooperation will also apply to Norway, the government declared in mid-August.
It is not known who stopped the tests, whether it was AstraZeneca itself or a regulatory body.
